CJC-1295 (No DAC) / GHRP-2Check methods and identity
What would establish the identity of both compounds in a mixture?
3 numbered sourcesSource years 2010–2025
Short chains of amino acids joined by peptide bonds can have similar names and different biological actions. CJC-1295 (No DAC) / GHRP-2 combines a name commonly used for the modified 29-residue growth hormone–releasing factor with pralmorelin, a six-residue peptide. A chemical identification of this exact pairing would have to account for both chains. [1, 2]
A 2010 Norwegian laboratory report offers an older example of identifying the no-DAC component. The investigators separated components of an unknown preparation and used high-resolution mass spectrometry to measure an intact peptide and smaller pieces of it. They proposed a sequence for a 29-residue peptide. The FDA later noted that its reported formula and mass were consistent with the no-DAC form, without establishing the salt form of the original material. [1, 3]
That paper studied one unknown sample, with no claim to have identified the two-peptide combination. In a mixture, researchers would need independent evidence for each chain. A measurement can be specific enough to distinguish a peptide from an unrelated compound yet insufficient to distinguish it from a closely related sequence. Looking at characteristic fragments can help make the assignment more specific. Identity, quantity and purity also answer different questions, even when all refer to the same preparation. [1, 3]
No recent primary analytical study of the exact GHRP-2 mixture was identified. The example shows the scope of a single-compound identification. The regulatory record for Japan's pralmorelin product establishes an identity for that approved diagnostic ingredient, and the Norwegian report supports a different identity in its own sample. Neither document characterizes the contents or stability of this catalog pairing. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
